Oxford Immunotec Learning Zone

Account Sign On

  Username/Password Help| Create Account

About Oxford Immunotec

Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company was founded in 2002 based on world-leading research at the University of Oxford. The European headquarters are located in Abingdon, UK and the North American headquarters are located in Marlborough, MA USA.

T-SPOT® technology is an innovative platform technology for diagnosing disease. The technology is a simple and accurate method of measuring a person's immune response to infection.

The company's first product is the T-SPOT®.TB test, the new cellular blood test for the detection of active and latent TB infection. The test was CE marked in Europe in July 2004, licensed in Canada in 2005 and was FDA approved in the United States in July of 2008.

Clinical Confidence:
  • 95.6% Sensitivity1
  • 97.1% Specificity1
  • Results unaffected by BCG vaccination, age or immunocompromised status1
Benefits of the T-SPOT.TB test:
  • Single blood test
  • Fast: next day results
  • Cost effective
  • No special lab equipment needed
  • "One and Done": no second visit required to read results

The T-SPOT.TB test addresses the unique requirements of all groups tested for TB:

Testing Coverage

The body of scientific evidence continues to grow on the performance of the T-SPOT.TB test. A significant number of peer-reviewed studies have been published worldwide in a variety of clinical and epidemiological settings.

Product Shot

Learn More at: http://www.oxfordimmunotec.com

1T-SPOT.TB Pivotal Clinical Study. Sensitivity of 95.6%, specificity of 97.1%. T-SPOT.TB results were not associated with immunocompromised status or BCG vaccination. T-SPOT.TB was not impacted by age. T-SPOT.TB Package Insert.